In which paediatric age group is MabThera (rituximab) indicated to induce remission in severe, active granulomatosis with polyangiitis or microscopic polyangiitis?

MabThera (rituximab), in combination with glucocorticoids, is indicated to induce remission in children aged 2 to less than 18 years with severe, active granulomatosis with polyangiitis or microscopic polyangiitis.